Skip to main content

Table 3 Selection of integrin inhibitors in preclinical studies and clinical trials

From: The functional role of integrins during intra- and extravasation within the metastatic cascade

Integrin Inhibitor

Target Integrin

Clinical trial

Intetumumab (CNTO 95)

αV

Phase II [129]

Abituzimab (DI17E6,

EMD 525797)

αV

Phase I/II [153]

MK-0429

αVß3

–

Cilengitide

(EMD 121974)

αVß3

αVß5

Phase II/III [135, 137]

D-pinitol

αVß3

–

GLPG0187

αVß3

Phase I [144]

Volociximab (M200)

α5ß1

Phase II [148]

PF-04605412

α5ß1

Phase I [149]